Sentiment Trading

OPKO Health Inc navigates a challenging Q1 2025 with strategic asset sales, cost-saving measures, and an optimistic revenue guidance, signaling a company in transition towards long-term growth and sustainability.

OPKO Health’s stock has been assigned a Neutral rating by JPMorgan, reflecting a cautious outlook amidst industry shifts and leadership changes, as the company navigates the evolving healthcare landscape.